Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ham, Jungoh, Costa, Carlotta, Sano, Renata, Lochmann, Timothy L., Sennott, Erin M., Patel, Neha U., Dastur, Anahita, Gomez-Caraballo, Maria, Krytska, Kateryna, Hata, Aaron N., Floros, Konstantinos V., Hughes, Mark T., Jakubik, Charles T., Heisey, Daniel A.R., Ferrell, Justin T., Bristol, Molly L., March, Ryan J., Yates, Craig, Hicks, Mark A., Nakajima, Wataru, Gowda, Madhu, Windle, Brad E., Dozmorov, Mikhail G., Garnett, Mathew J., McDermott, Ultan, Harada, Hisashi, Taylor, Shirley M., Morgan, Iain M., Benes, Cyril H., Engelman, Jeffrey A., Mossé, Yael P., Faber, Anthony C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749542/
https://www.ncbi.nlm.nih.gov/pubmed/26859456
http://dx.doi.org/10.1016/j.ccell.2016.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749542/
https://www.ncbi.nlm.nih.gov/pubmed/26859456
http://dx.doi.org/10.1016/j.ccell.2016.01.002

Ejemplares similares